Contact information

Sylentis, SAU
Parque Tecnológico PCM C/Santiago Grisolía, 2
Tres Cantos
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
    • Therapeutic areas
      • Analgesia & Pain
      • Inflammatory diseases
      • Immunology
      • Ophtalmology and optometry
      • Digestive system and hepatology
      • Central nervous system

Sylentis focuses on researching new therapeutic approaches based on gene silencing. Sylentis is specialised in developing therapies via interference RNA, a powerful tool for rational drug design.

Products and services

We are developing treatments for glaucoma and dry eye syndrome. Sylentis is also focusing on inflammatory bowel disease. Furthermore, Sylentis is focusing on post-traumatic neuron lesions and ischaemia, neurodegenerative diseases and dementia.

Areas of interest for future collaborations

Because the release of RNAi in the body is an important part of these technologies, the company has a number of research projects under way regarding the controlled release of drugs, in cooperation with various public and private institutions.

Biotech Sanitaria

Drugs National Companies
Product / Service Type Therapeutic area Development phase
Tivanisirán (SYL1001) Biodrugs/ Drugs Oftalmología y optometría P III
SYL1801 Biodrugs/ Drugs Oftalmología y optometría P II